^
    Back
    Association details:
    Biomarker:BRAF mutation
    Cancer:Melanoma
    Drug:bemcentinib (BGB324) (AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    2087 / 5 - AXL inhibition enhances Type 1 interferon (IFN) response and potentiates chemo-immunotherapy

    Published date:
    03/09/2022
    Excerpt:
    In addition, bemcentinib treatment in conjunction with i.t. doxorubicin enhanced Type 1 IFN response, reduced cancer stemness and epithelial to mesenchymal (EMT) gene expression in this model. Furthermore, this combination treatment regimen sensitized the immune checkpoint inhibitor refractory Braf-mutant melanoma (YUMM1.7) by enhancing the type 1 IFN response resulting in significantly improved median overall survival.
    Secondary therapy:
    doxorubicin hydrochloride